BTIG Research initiated coverage on shares of Orchestra BioMed (NASDAQ:OBIO – Free Report) in a report released on Thursday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $12.

BTIG analyst Marie Thibault initiated coverage of Orchestra BioMed (OBIO) with a Buy rating and $12 price target Orchestra is a medical ...

NEW HOPE, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company ...

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO – Get Free Report)’s share price traded up 3.4% on Friday .The company traded as high as $4.35 and last traded at $4.23. 38,786 shares traded hands ...

Medical device industry veteran brings over three decades of expertise in M&A, as well as structured research and development (“R&D”) collaborations aligned with Orchestra BioMed’s ...

Orchestra BioMed Holdings, Inc. announced promising echocardiographic data regarding atrioventricular interval modulation (AVIM) therapy's impact on patients with diastolic dysfunction at the THT ...

Fintel reports that on March 20, 2025, BTIG initiated coverage of Orchestra BioMed Holdings (NasdaqGM:OBIO) with a Buy recommendation. Analyst Price Forecast Suggests 247.03% Upside As of March 19, ...

Riley Securities Precision Oncology & RadioPharma Conference on February 28, 2025. Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to ...

Riley Securities Precision Oncology & RadioPharma Conference on February 28, 2025. Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients ...